Wynn Capital LLC Has $2.10 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Wynn Capital LLC grew its position in Amgen Inc. (NASDAQ:AMGN) by 1.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,528 shares of the medical research company’s stock after purchasing an additional 103 shares during the quarter. Amgen comprises approximately 1.4% of Wynn Capital LLC’s investment portfolio, making the stock its 18th biggest position. Wynn Capital LLC’s holdings in Amgen were worth $2,103,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Strategic Financial Concepts LLC bought a new stake in shares of Amgen in the second quarter valued at approximately $26,000. Hershey Financial Advisers LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at $30,000. nVerses Capital LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at $33,000. Finally, Matrix Trust Co acquired a new stake in shares of Amgen in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. TD Cowen raised their target price on Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 target price (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Wells Fargo & Company downgraded Amgen from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Barclays raised their price objective on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $380.00 price objective (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $326.30.

Amgen Stock Performance

Shares of AMGN opened at $328.35 on Friday. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The stock has a 50-day moving average of $326.06 and a 200-day moving average of $310.55. The company has a market cap of $176.43 billion, a PE ratio of 56.51, a P/E/G ratio of 2.86 and a beta of 0.61. Amgen Inc. has a one year low of $249.70 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.00 earnings per share. On average, equities research analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a dividend of $2.25 per share. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.74%. Amgen’s dividend payout ratio (DPR) is currently 154.91%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.